IPO - Profile

Qilian International Holding Group Limited

Health Care > Other Pharmaceuticals

QLI

Summary

Through our wholly owned indirect subsidiaries and the contractual arrangements described below, we are a pharmaceutical and chemical company based in China that focuses on the development, manufacture, marketing, and sale of oxytetracycline products, licorice products, traditional Chinese medicine derivatives (“TCMD”) product, heparin product, sausage casings, and fertilizers. We independently developed all of our products within our research and development department. Our products are sold in more than 20 provinces in China.

     ·    Our licorice products include Gan Di Xin®, Qilian Shan® Licorice Extract, and Qilian Shan® Licorice Liquid Extract. More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$5.00 5,000,000 Positive High 0%

Offering Team

  • Legal counsel
  • Hunter Taubman Fischer & Li LLC
  • Auditors
  • Friedman LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 11 Jan, 2021

Offer 14 Jan, 2021

Look Ahead

Lock Up Expiry Jul 14, 2021

IPO Terms

Offer Price $5.00
Offer Size 5M

Market Sentiments

Stock Price